Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT02514967 Org: User:
Start: 06/30/16 End: 02/28/17 Due: 02/28/18

Phase III ALTU-135 CP Safety Trial

Phase: N/A Priority: Normal
NCT ID: NCT00500084 Org: User:
Start: 12/31/07 End: 03/31/09 Due: 03/31/10

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02279498 Org: User:
Start: 06/30/15 End: 01/20/17 Due: 01/20/18

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Phase: N/A Priority: Normal
NCT ID: NCT01305746 Org: User:
Start: 04/30/11 End: 10/31/13 Due: 10/31/14

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

Phase: N/A Priority: Normal
NCT ID: NCT00455546 Org: User:
Start: 04/30/07 End: 09/30/07 Due: 09/30/08

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02734810 Org: User:
Start: 06/30/16 End: 03/31/17 Due: 03/31/18

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT00449878 Org: User:
Start: 05/31/07 End: 06/30/08 Due: 06/30/09

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01359605 Org: User:
Start: 06/30/11 End: 07/31/11 Due: 07/31/12

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT01598857 Org: User:
Start: 12/31/14 End: - Due: -

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03051490 Org: User:
Start: 04/28/17 End: 06/30/18 Due: 06/30/19

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01162681 Org: User:
Start: 07/31/10 End: 04/30/12 Due: 04/30/13

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01395745 Org: User:
Start: 02/28/13 End: 10/31/16 Due: 10/31/17

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

Phase: N/A Priority: Normal
NCT ID: NCT01522196 Org: User:
Start: 02/29/12 End: 03/31/12 Due: 03/31/13

EASY: Extended Access to Sollpura Over Years

Phase: N/A Priority: Normal
NCT ID: NCT02823964 Org: User:
Start: 09/30/16 End: 03/31/18 Due: 03/31/19

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT02052219 Org: User:
Start: 10/31/14 End: 10/31/21 Due: 10/31/22

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT00095732 Org: User:
Start: 06/30/04 End: 03/31/05 Due: 03/31/06

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01130246 Org: User:
Start: 05/31/10 End: 03/31/12 Due: 03/31/13

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT01359579 Org: User:
Start: 06/30/11 End: 06/30/12 Due: 06/30/13

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

Phase: N/A Priority: Normal
NCT ID: NCT00525954 Org: User:
Start: 09/30/07 End: 12/31/07 Due: 12/31/08

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Phase: N/A Priority: Normal
NCT ID: NCT01609452 Org: User:
Start: 12/31/15 End: - Due: -

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT02074020 Org: User:
Start: 12/31/15 End: - Due: -

Open-Label Phase III Long-Term Safety Trial of Liprotamase

Phase: N/A Priority: Normal
NCT ID: NCT00449904 Org: User:
Start: 06/30/07 End: 04/30/09 Due: 04/30/10

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Phase: N/A Priority: Normal
NCT ID: NCT02062684 Org: User:
Start: 06/30/13 End: 06/30/17 Due: 06/30/18

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00743925 Org: User:
Start: 07/31/08 End: 04/30/10 Due: 04/30/11

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00434473 Org: User:
Start: 12/31/06 End: 12/31/09 Due: 12/31/10